Active, not recruitingPhase 4NCT04616963

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

Studying Acquired immunodeficiency

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Diego
Principal Investigator
Sheldon Morris, MD, LMFT
UC San Diego AntiViral Research Center (AVRC)
Intervention
Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg(drug)
Enrollment
64 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04616963 on ClinicalTrials.gov

Other trials for Acquired immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Acquired immunodeficiency →

← Back to all trials